The OncoRat® Is The Ideal Host For Patient-Derived Xenografts Of Ovarian Cancer Cells
Ovarian cancer is the most lethal gynecological cancer in the [...]
H358 NSCLC Xenografts In Humanized Rats: The Ideal In Vivo Model For Studying KRAS Mutations
Lung adenocarcinomas, the major histological subtype of non-small cell lung [...]
Hera Biolabs Announces Molecular Cancer Therapeutics Publication On Immunodeficient Rats For Oncology Research
Hera Biolabs, the University of Michigan, Case Western Reverse University and other collaborators are announcing a recent publication in the American Association for Cancer Research (AACR) journal, Molecular Cancer Therapeutics, entitled, "Sprague Dawley Rag2-null rats created from engineered spermatogonial stem cells are immunodeficient and permissive to human xenografts."
Breakthroughs In Gene Editing Allow For The Creation Of Superior Preclinical Oncology Models
Gene editing is getting a lot of attention in the [...]
The OncoRat®: Hosting Valuable Tumor Xenograft Models That Are Difficult Or Impossible To Study Using In Vitro Or Mouse Models
One of the most widely used methods of modeling human [...]
Patient Derived Xenograft Studies From Wider Varieties Of Patient Sub-Populations Promise Improved Clinical Trial Selection And Design
Around 85% of preclinical drugs entering clinical trials in oncology never make it past Phase 1 because they fail to demonstrate sufficient efficacy due to testing in unselected patient populations 1-3. Many of these failed agents are targeted therapies, meaning that they target specific oncogenic driver mutations. However, not all tumors harbor the same, or even similar, driving mutations – these targeted therapies are often found to be beneficial in very small patient populations which would not be captured in an unselected-patient trial design.
OncoRat® PDX Models Highlighted In Drug Discovery News (DDN) Special Report On Cancer: Aiming For Avatars
While advances in in-vitro platforms have allowed researchers to better visually monitor a variety of aspects of tumor biology, a significant limitation of 3D cultured models for patient therapeutic monitoring or “patient avatars” is the lack of important components, such as the influence of surrounding tissues and potential cell-to-cell interactions, when studying cancer progression, treatment responses and outcomes. Patient derived xenograft models or PDX models overcome these limitations and other research challenges and provide a platform that is believed to more closely mimic the patient tumor.
Understanding Transporter-Mediated Drug-Drug Interactions Using Humanized Liver Mice
Pharmaceutical researchers and regulators are increasingly aware of the influence [...]
Using Patient Derived Xenografts To Improve Therapeutic Cancer Treatments
An increased understanding of human tumors has created a solid [...]
Humanized Mouse Models Advance Immunotherapeutic Strategies In Treatment Of Type 1 Diabetes
A relatively common autoimmune disease, Type 1 Diabetes (T1D) is [...]